Pular para o conteúdo principal
Ranking Invest

AXGN - AxoGen, Inc.

Segmento: HealthcareAxoGen, Inc., together with its subsidiaries, develops and markets surgical solutions for physical damage or transection to peripheral nerves. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments. Its products also comprise Axoguard Nerve Cap, a porcine submucosa ECM product that is used to protect a peripheral nerve end, as well as separates the nerve from the surrounding environment to reduce the development of symptomatic or painful neuroma; and Avive Soft Tissue Membrane, a processed human umbilical cord membrane that can be used as a resorbable soft tissue covering to separate tissues in the surgical bed. In addition, the company offers AxoTouch two point discriminator, a tool that is used for measuring the innervation density of surface area of the skin. It provides its products to hospitals, surgery centers, and military hospitals plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and various oral and maxillofacial surgeons in the United States, Canada, Germany, the United Kingdom and other European countries, South Korea, and internationally. AxoGen, Inc. is headquartered in Alachua, Florida.

Análise Ranking Invest

Valuation estimado
-10,49%
$ 194.50 Mi
Valor de Mercado
$ 2.27 Bi
Sobrepreço (AV)+1065.6%
IVR
0.09A companhia vale 0,09 vezes o seu valor de mercado atual de acordo com a estimativa do Ranking Invest.
IVR2
-0.03O valuation alternativo equivale a -3% do valor de mercado da companhia.
MLL
-0.03O lucro líquido dos controladores em 16 trimestres equivale a -3% do valor de mercado.
Último Balanço Atualizado: 2T2026

O Ranking Invest utiliza metodologia própria baseada em dados financeiros objetivos, considerando patrimônio, lucratividade e endividamento para estimar o valuation das empresas.

Dados da Empresa

Patrimônio Líquido

$ 256.26 Mi

Dívida Líquida

-$ 94.57 Mi

L4T

-$ 33.55 Mi

MM4T

-13.71%

Indicadores Básicos

ROE

-13.09%

Índices de Previsibilidade

Receita Líquida

B0.04

Lucro

D0.72

Margem

D0.75

Índices de Tendência

Receita Líquida

A11.48

Lucro

D-1.63

Margem

D1.42

Índices de Endividamento

DIV/PAT

-0.37

DIV/L4T

2.82

Dívidas
Cotação
Gráfico Lucro/Receita Líquida X TrimestrePor padrão são exibidos os últimos 16 trimestres; quando houver mais trimestres disponíveis, use o botão junto à tabela de resultados para expandir o histórico.